Published phase III RCTs indicate that apixaban, dabigatran, rivaroxaban, and edoxaban present similar or lower risks of VTE and bleeding than VKAs in patients with normal weight.[35–38] Our meta-analysis, featuring subgroup analysis by different types of NOACs, supports these findings, demonstrating the superiority of Factor Xa inhibitors over VKAs in terms of efficacy and safety in patients with morbid obesity or high body weight. The gene discussed is F10; the disease is morbid obesity.